Cardiovascular risk in ADT recipients: does the type of ADT matter?

Prostate Cancer Prostatic Dis. 2024 Sep;27(3):435-437. doi: 10.1038/s41391-024-00832-0. Epub 2024 Apr 25.

Authors

Jehonathan H Pinthus^{1

2}, Wilhelmina C M Duivenvoorden^{3

4}

Affiliations

¹ Department of Surgery, Division of Urology, Faculty of Medicine, McMaster University, Hamilton, ON, Canada. [email protected].
² Research Institute of St. Joe's Hamilton, Hamilton, ON, Canada. [email protected].
³ Department of Surgery, Division of Urology, Faculty of Medicine, McMaster University, Hamilton, ON, Canada.
⁴ Research Institute of St. Joe's Hamilton, Hamilton, ON, Canada.

PMID: 38664503
DOI: 10.1038/s41391-024-00832-0

No abstract available

Publication types

Editorial
Review

MeSH terms

Androgen Antagonists* / adverse effects
Androgen Antagonists* / therapeutic use
Cardiovascular Diseases* / chemically induced
Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / etiology
Heart Disease Risk Factors
Humans
Male
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / pathology
Risk Factors

Substances

Androgen Antagonists